19 Harley St, London, W1G 9QJ, UK

Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study

AIMS: The overall prognosis of chordoma is poor, and current treatment options are limited. The insulin-like growth factor 1 receptor (IGF-1R) pathway is important for cell signalling, and attractive for selective inhibition. We investigated the expression of IGF-1R and its ligands, IGF-1 and IGF-2, in a series of 50 chordomas, in order to assess whether IGF-1R-signalling could be a potential target for specific inhibition in chordomas. METHODS AND RESULTS: Fifty chordomas (34 primary tumours, 16 recurrences) from 44 patients were evaluated immunohistochemically for the expression of IGF-1R, IGF-1 and IGF-2. Thirty-eight chordomas (76%) expressed IGF-1R, 46 (92%) expressed IGF-1 and 25 (50%) expressed IGF-2. Semi-quantitative analyses revealed a moderate to strong staining intensity in >/= 50% of tumour cells for IGF-1R, IGF-1 and IGF-2 in 18 (36%), 32 (64%) and eight (16%) chordomas, respectively. Tumour volume correlated significantly with IGF-1R-staining intensity in primary chordomas (P = 0.042). CONCLUSIONS: IGF-1R and IGF-1 are expressed in the majority of chordomas. IGF-1 expression is much stronger than IGF-2 expression. Patients whose chordomas show a moderate to strong staining intensity in >/= 50% of tumour cells for IGF-1R (36%) might benefit most from IGF-1R targeting, particularly if they suffer from large and surgically non-resectable chordomas

Keywords : Adult,Age Factors,Aged,Aged,80 and over,Austria,Biomarkers,Biomarkers,Tumor,Chordoma,diagnosis,epidemiology,Female,Germany,Growth,Humans,Insulin-Like Growth Factor I,Insulin-Like Growth Factor II,Ligands,Male,metabolism,methods,Middle Aged,Molecular Targeted Therapy,mortality,Neoplasm Recurrence,Local,Patients,Prognosis,Receptor,IGF Type 1,Recurrence,Retrospective Studies,Spinal Neoplasms,surgery,Survival Rate,Universities,Young Adult,, Insulinlike,Growth,Factor1,Receptor, piriformis syndrome pain relief

Date of Publication : 2012 May

Authors : Scheipl S;Froehlich EV;Leithner A;Beham A;Quehenberger F;Mokry M;Stammberger H;Varga PP;Lazary A;Windhager R;Gattenloehner S;Liegl B;

Organisation : Department of Orthopaedics and Orthopaedic Surgery, Medical University of Graz, Graz, Austria

Journal of Publication : Histopathology

Pubmed Link : https://www.ncbi.nlm.nih.gov/pubmed/22372631

The London Spine Unit : Harley Street UK. Specialists in Cutting Edge Technologies for Spinal Surgery

Make an Appointment 

Trustpilot Reviews
Doctify Reviews
Top Doctor Reviews

Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study | Cost of nerve block injection

What our patients say ...

Consultant Spine Surgeon
Consultant Spine Surgeon
Consultant Spine Surgeon

This surgical technique consists of a percutaneous approach for the treatment of small to medium size hernias of the intervertebral disc by laser energy. The main objective is to reduce the intradiscal pressure in the nucleus pulposus

Laser Disc Surgery can be performed under local anaesthetic as a day case at our centre on the prestigious Harley Street.
What is London spine unit and How it Works

The London Spine Unit was established in 2005 and has successfully treated over 5000 patients. All conditions are treated.

treatment of all spinal disorders

The London Spine Unit specialises in Minimally Invasive Treatments allowing rapid recovery and return to normal function

Trusted by patients worldwide

The London Spine Unit provides the highest quality care to all patients and has VIP services for those seeking exceptional services

If you have any emergency Doctor’s need, simply call our 24 hour emergency

Your personal case manager will ensure that you receive the best possible care.

Call Now 

+44 844 589 2020
+44 203 973 8810